Pasar al contenido principal

DESARROLLO DE NUEVAS VACUNAS RNA ANTIANGIOGENICAS PARA PREVENIR LA METASTASIS TUMORAL

PID2022-136735OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓN RIOJA SALUD

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes

  • Corzana, Francisco
  • Asín, Alicia
  • Eguskiza, Ander
  • De Tomi, Elisa
  • Martín-Carnicero, Alfonso
  • Martínez-Moral, María P.
  • Mangini, Vincenzo
  • Papi, Francesco
  • Bretón, Carmen
  • Oroz, Paula
  • Lagartera, Laura
  • Jiménez-Moreno, Ester
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Nativi, Cristina
  • Asensio, Juan Luis
  • Hurtado-Guerrero, Ramón
  • Peregrina, Jesús M.
  • Malerba, Giovanni
  • Martínez, Alfredo
  • Fiammengo, Roberto
Pancreatic cancer is one of the deadliest cancers worldwide, mainly due to late diagnosis. Therefore, there is an urgent need for novel diagnostic approaches to identify the disease as early as possible. We have developed a diagnostic assay for pancreatic cancer based on the detection of naturally occurring tumor associated autoantibodies against Mucin-1 (MUC1) using engineered glycopeptides on nanoparticle probes. We used a structure-guided approach to develop unnatural glycopeptides as model antigens for tumor-associated MUC1. We designed a collection of 13 glycopeptides to bind either SM3 or 5E5, two monoclonal antibodies with distinct epitopes known to recognize tumor associated MUC1. Glycopeptide binding to SM3 or 5E5 was confirmed by surface plasmon resonance and rationalized by molecular dynamics simulations. These model antigens were conjugated to gold nanoparticles and used in a dot-blot assay to detect autoantibodies in serum samples from pancreatic cancer patients and healthy volunteers. Nanoparticle probes with glycopeptides displaying the SM3 epitope did not have diagnostic potential. Instead, nanoparticle probes displaying glycopeptides with high affinity for 5E5 could discriminate between cancer patients and healthy controls. Remarkably, the best-discriminating probes show significantly better true and false positive rates than the current clinical biomarkers CA19-9 and carcinoembryonic antigen (CEA)., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No956544. We thank Dr. Sara Gasperini of the General Pathology Section, Department of Medicine, University of Verona, for providing access and assistance with the LI–COR Odyssey Infrared Imaging System. We thank Prof.Henrik Clausen from Copenhagen Center for Glycomics atUniversity of Copenhagen for his insightful comments. F.C.thanks the Mizutani Foundation for Glycoscience (grant220115) and AECC (INNOVA 2023 project). A.A. and C.B.thank the Asociación Española Contra el Cáncer (AECC),sección La Rioja, for their doctoral fellow ships. We thank the ALBA (Barcelona, Spain) synchrotron beamline XA-LOC. We thank ARAID, the Agencia Estatal de Investiga-ción (AEI, BFU201675633-P, PID2019-105451GB-I00, and PID2022-136362NB-I00 to R.H.-G., PID2022-136735OB-I00to A.M., PID2021-127030OA-I00 to E.J.-M, PID2022-141085NB-100 to J.L.A, and PID2021-127622OB-I00 andPDC2022-133725-C21 to F.C. and J.H.B.), Universidad de La Rioja (REGI22/47 and REGI22/16), Gobierno de Aragón (E34_R17 and LMP58_18 to R.H.-G.) with FEDER(2014–2020) funds for “Building Europe from Aragón” forfinancial support, and the COST Action CA18103 INNO-GLY: Innovation with Glycans new frontiers from synthesis to new biological targets. CN thanks Fondazione AIRC,project IG25762. Open Access publishing facilitated byUniversità degli Studi di Verona, as part of the Wiley -CRUI-CARE agreement., Peer reviewed